Cerebrolysin
Porcine-derived neuropeptide complex containing low-molecular-weight peptides (<10 kDa) and free amino acids with neurotrophic factor–mimetic activity
- Class
- Neuropeptide complex
- Half-life
- ~10 min
- Route
- Intramuscular
- Cadence
- Daily
- Evidence
- Mixed / early human
Overview
<cite index="2-7,10-9,10-10">Cerebrolysin is a standardised mixture of low-molecular-weight neuropeptides (below 10 kDa) and free amino acids extracted via enzymatic breakdown of porcine brain proteins — 25% peptides, 75% amino acids.</cite> <cite index="10-9,27-1">The peptide fraction contains fragments that mimic brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF).</cite> <cite index="10-3">It crosses the blood-brain barrier</cite> and has been used in Europe and Asia for decades to support recovery after stroke, traumatic brain injury (TBI), and for cognitive impairment in dementia — but it's not FDA-approved, and the evidence picture is mixed.
<cite index="2-8">The strongest clinical data come from traumatic brain injury: a double-blind RCT (n=142) showed 68% good recovery vs 48% on placebo at 90 days (Glasgow Outcome Scale Extended).</cite> <cite index="7-5">Stroke data show a medium-to-large effect on NIHSS (National Institutes of Health Stroke Scale) at 30 days in the recovery window,</cite> but <cite index="2-9">only when treatment begins within 12 hours of event onset — delayed initiation beyond 48 hours produces null results.</cite> <cite index="2-4">Alzheimer's disease trials show positive trends in ADAS-cog scores but with high heterogeneity between studies,</cite> and <cite index="8-3,8-7">benefits plateau after 6 months and reverse within 3 months of discontinuation, suggesting symptomatic benefit without disease modification.</cite>
<cite index="12-2,12-16">A large 2012 trial cast doubt on its usefulness in stroke except perhaps in severe cases.</cite> <cite index="18-3">The 2023 Cochrane update found no beneficial effect on all-cause death in acute ischemic stroke, alongside a statistically significant increase in non-fatal serious adverse events.</cite> <cite index="1-8">It's never gained FDA approval in the United States due to insufficient large-scale trial data meeting FDA endpoints.</cite> Most of the positive trials are industry-sponsored; independent replication is limited. Side effects are usually mild (dizziness, headache, agitation) but <cite index="25-4,25-6">fulminant anaphylaxis has been documented</cite> and <cite index="20-2">it's contraindicated in epilepsy and severe renal impairment.</cite>
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- <cite index="1-8,12-2">Not approved by FDA, EMA for routine use; regulatory status unclear in many countries.</cite> Sold in research markets without standardised oversight — actual peptide composition may vary between suppliers.
- <cite index="17-5,22-1">Porcine allergy is an absolute contraindication.</cite> <cite index="25-4,25-6">Fulminant anaphylactic reactions have been documented.</cite> First infusion should be medically supervised with emergency equipment on hand.
- <cite index="8-8,20-2">Lowers seizure threshold — contraindicated in active epilepsy.</cite> Use with extreme caution if you have a history of seizures.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Cerebrolysin.
- Cognitive testing (MMSE, MoCA, or domain-specific assessments)
- Functional recovery scores (NIHSS for stroke, Glasgow Outcome Scale for TBI, mRS for disability)
- Mood and subjective brain-fog scores
- Allergic reaction signs (dizziness, flushing, respiratory distress — especially first infusion)
- Seizure threshold if predisposed (Cerebrolysin lowers it)
- Renal function if impaired at baseline
Frequently asked questions
What is Cerebrolysin?
Porcine-derived neuropeptide complex containing low-molecular-weight peptides (<10 kDa) and free amino acids with neurotrophic factor–mimetic activity. <cite index="2-7,10-9,10-10">Cerebrolysin is a standardised mixture of low-molecular-weight neuropeptides (below 10 kDa) and free amino acids extracted via enzymatic breakdown of porcine brain proteins — 25% peptides, 75% amino acids.</cite> <cite index="10-9,27-1">The peptide fraction contains fragments that mimic brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and glial cell-line-derived neurotrophic factor (GDNF).</cite> <cite index="10-3">It crosses the blood-brain barrier</cite> and has been used in Europe and Asia for decades to support recovery after stroke, traumatic brain injury (TBI), and for cognitive impairment in dementia — but it's not FDA-approved, and the evidence picture is mixed.
How is Cerebrolysin administered?
Intramuscular, typically daily.
What is the half-life of Cerebrolysin?
~10 min — Individual peptide components (e.g. BDNF) are short-lived in plasma; neurotrophic effects persist for weeks post-treatment.
Is Cerebrolysin approved for human use?
Cerebrolysin is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Cerebrolysin?
Evidence tier: Mixed / early human. <cite index="2-8">Double-blind RCT (n=142, TBI): 68% good recovery on Cerebrolysin vs 48% placebo at 90 days (Glasgow Outcome Scale Extended).</cite>
What is commonly monitored when researching Cerebrolysin?
Commonly tracked markers + signals: Cognitive testing (MMSE, MoCA, or domain-specific assessments), Functional recovery scores (NIHSS for stroke, Glasgow Outcome Scale for TBI, mRS for disability), Mood and subjective brain-fog scores, Allergic reaction signs (dizziness, flushing, respiratory distress — especially first infusion), Seizure threshold if predisposed (Cerebrolysin lowers it), Renal function if impaired at baseline.
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.